Figure 2.

Viability of U87MG (% of control) after incubation with EEP and temozolomide. Control – (1), Temozolomide (2 - TMZ 20 μM), EEP (3 - 10 μg/ml, 5 - 20 μg/ml, 7 - 30 μg/ml, 9 - 50 μg/ml, 11 - 100 μg/ml), EEP administered together with temozolomide (4 – EEP 10 μg/ml + TMZ 20 μM, 6 - EEP 20 μg/ml + TMZ 20 μM, 8 - EEP 30 μg/ml + TMZ 20 μM, 10 - EEP 50 μg/ml + TMZ 20 μM, 12 - EEP 100 μg/ml + TMZ 20 μM). Viability of U87MG cells after 24 (A), 48 (B) and 72 (C) hours of incubation. The results are presented as a percentage of control. A/#p < 0.05, ##p < 0.01, ###p < 0.001, vs. control; *p < 0.05, ***p < 0.001, vs. TMZ; p < 0.05, ▲ ▲ p < 0.01, ▲ ▲ ▲ p < 0.001, vs. EEP; B/ ###p < 0.001, vs. control; *p < 0.05; **p < 0.01; ***p < 0.001, vs. TMZ; ▲ ▲ p < 0.01, vs. EEP; C/###p < 0.001, vs. control; *p < 0.05, ***p < 0.001, vs. TMZ; p < 0.05, ▲ ▲ ▲ p < 0.001, vs. EEP. All statistical analysis were performed using Student-t test.

Markiewicz-Żukowska et al. BMC Complementary and Alternative Medicine 2013 13:50   doi:10.1186/1472-6882-13-50
Download authors' original image